- Home
- NTIP vs SCYX Comparison
NTIP vs SCYX Comparison
Compare NTIP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- SCYX
- Stock Information
- Founded
- NTIP 1990
- SCYX 1999
- Country
- NTIP United States
- SCYX United States
- Employees
- NTIP N/A
- SCYX N/A
- Industry
- NTIP Multi-Sector Companies
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- SCYX Health Care
- Exchange
- NTIP Nasdaq
- SCYX Nasdaq
- Market Cap
- NTIP 28.6M
- SCYX 28.5M
- IPO Year
- NTIP 1998
- SCYX 2014
- Fundamental
- Price
- NTIP $1.25
- SCYX $0.69
- Analyst Decision
- NTIP
- SCYX
- Analyst Count
- NTIP 0
- SCYX 0
- Target Price
- NTIP N/A
- SCYX N/A
- AVG Volume (30 Days)
- NTIP 13.6K
- SCYX 127.6K
- Earning Date
- NTIP 08-11-2025
- SCYX 08-07-2025
- Dividend Yield
- NTIP 8.33%
- SCYX N/A
- EPS Growth
- NTIP N/A
- SCYX N/A
- EPS
- NTIP N/A
- SCYX N/A
- Revenue
- NTIP $250,000.00
- SCYX $2,630,000.00
- Revenue This Year
- NTIP N/A
- SCYX $463.61
- Revenue Next Year
- NTIP N/A
- SCYX $310.80
- P/E Ratio
- NTIP N/A
- SCYX N/A
- Revenue Growth
- NTIP N/A
- SCYX N/A
- 52 Week Low
- NTIP $1.16
- SCYX $0.66
- 52 Week High
- NTIP $1.78
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- NTIP 51.99
- SCYX 37.15
- Support Level
- NTIP $1.20
- SCYX $0.67
- Resistance Level
- NTIP $1.30
- SCYX $0.75
- Average True Range (ATR)
- NTIP 0.05
- SCYX 0.04
- MACD
- NTIP 0.00
- SCYX 0.00
- Stochastic Oscillator
- NTIP 64.29
- SCYX 25.54
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.